Last reviewed · How we verify
COVID-19 Screening Program
trial testing Self-administered saliva-based viral testing in COVID-19 in 61 participants. Completed in 1 July 2022.
| Lead sponsor | University of Pennsylvania |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 61 |
| Start date | 7 February 2022 |
| Primary completion | 1 July 2022 |
| Estimated completion | 1 July 2022 |
| Sites | 1 location across United States |
University of Pennsylvania
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
How often they use the POC screening program
| Group | Value | 95% CI |
|---|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 238 |
Self-reported acceptability of implementing POC screening program using the Acceptability of Intervention Measure (i.e., "Point of care testing is acceptable to me"). Scale values: 1 (completely disagree) to 5 (completely agree).
| Group | Value | 95% CI |
|---|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 4.36 | ± 0.72 |
Self-reported appropriateness of implementing POC screening program using the Intervention Appropriateness Measure (i.e., "Point of care testing seems appropriate."). Scale values: 1 (completely disagree) to 5 (completely agree).
| Group | Value | 95% CI |
|---|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 4.40 | ± 0.72 |
Self-reported feasibility of implementing POC screening program using the Feasibility of Intervention Measure (i.e., "Point of care testing seems feasible."). Scale values: 1 (completely disagree) to 5 (completely agree).
| Group | Value | 95% CI |
|---|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 4.29 | ± 0.75 |
Self-report of if participant received any positive test results from saliva-based viral test or Clinical Laboratory Improvement Amendments (CLIA) approved test
| Group | Value | 95% CI |
|---|---|---|
| PSOM Staff, Trainees, or Faculty Who Participate in the Point of Care Testing | 1 |
In view of the recent COVID surge and difficulties in obtaining testing, we aim to increase Point of Care (POC) testing, whereby University of Pennsylvania (Penn) faculty, staff, and trainees who are working in person at Perelman School of Medicine (PSOM) laboratories can self-test. The purpose of this study is to evaluate the implementation of this POC testing program. We will not be collecting any samples as part of this study. This will ensure that individuals can rapidly identify if they have COVID-19 while balancing use, acceptability, appropriateness, and feasibility. We will start with a pilot phase whereby we will evaluate the implementation of a POC version of COVID-19 screening program that will coordinate several existing systems at the University of Pennsylvania including voluntary, self-administered saliva-based viral testing. We will pilot this program to a small cohort of PSOM labs and then test implementation of the self-testing of the POC version of COVID-19 screening across all PSOM labs for those who wish to participate. All results will be self-reported and will not be used to validate any tests or support any future approval from the FDA. No data from this study will go into the participants' Electronic Medical Record (EMR).
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05216627.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing